Indeed, in the recent open-label, randomized, controlled, multicenter study (PIONEER AF-PCI) involving 2124 stented patients with AF, both low-dose rivaroxaban (15 mg once daily) plus a P2Y12 inhibitor and very-low-dose rivaroxaban (2.5 mg twice daily) plus DAPT were associated with lower bleeding risks than standard triple therapy with a vitamin K antagonist plus DAPT. Here, P2RY12 is linked to atrial fibrillation.